Planning Directions Inc. Buys Shares of 96,107 Pfizer Inc. (NYSE:PFE)

Planning Directions Inc. acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 96,107 shares of the biopharmaceutical company's stock, valued at approximately $2,435,000. Pfizer comprises approximately 1.0% of Planning Directions Inc.'s portfolio, making the stock its 23rd largest holding.

A number of other large investors have also made changes to their positions in PFE. Norges Bank purchased a new position in Pfizer during the fourth quarter worth about $2,328,986,000. Starboard Value LP purchased a new position in shares of Pfizer in the 4th quarter worth about $407,730,000. Assenagon Asset Management S.A. raised its holdings in shares of Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. raised its holdings in shares of Pfizer by 1,106.0% in the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock worth $143,967,000 after purchasing an additional 5,153,257 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE traded up $0.21 during mid-day trading on Thursday, hitting $25.77. The stock had a trading volume of 39,477,537 shares, compared to its average volume of 41,794,796. The company has a market cap of $146.49 billion, a PE ratio of 18.67, a PEG ratio of 0.93 and a beta of 0.58. The company's fifty day simple moving average is $23.82 and its two-hundred day simple moving average is $24.82. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.82 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.68%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Wolfe Research raised their price objective on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Morgan Stanley raised their target price on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, Citigroup raised their target price on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and an average target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.